Beraprost sodium ameliorates cognitive impairment by promoting oligodendrocyte precursor cell proliferation and differentiation in vascular cognitive impairment mouse model

IF 4.6 2区医学 Q1 NEUROSCIENCES

Neuropharmacology Pub Date : 2025-06-03 DOI:10.1016/j.neuropharm.2025.110547

Mengsha Hu , Bingsong Xu , Linzhi Ge , Huijie Bian , Chao Zhou , Shengnan Xia , Haiyan Yang , Xinyu Bao , Hui Zhao , Yun Xu , Shu Shu

{"title":"Beraprost sodium ameliorates cognitive impairment by promoting oligodendrocyte precursor cell proliferation and differentiation in vascular cognitive impairment mouse model","authors":"Mengsha Hu , Bingsong Xu , Linzhi Ge , Huijie Bian , Chao Zhou , Shengnan Xia , Haiyan Yang , Xinyu Bao , Hui Zhao , Yun Xu , Shu Shu","doi":"10.1016/j.neuropharm.2025.110547","DOIUrl":null,"url":null,"abstract":"<div><div>Chronic cerebral hypoperfusion (CCH) leads to white matter injury (WMI), a key contributor to the development of vascular cognitive impairment (VCI). Beraprost sodium (BPS) is a chemically stable and orally active prostaglandin I<sub>2</sub> (PGI<sub>2</sub>) analog, while the role and mechanism of BPS in VCI have not been well understood. In this study, we used a mouse model of bilateral carotid artery stenosis (BCAS mice) and demonstrated that BPS treatment facilitated the proliferation and differentiation of oligodendrocyte precursor cells (OPCs), potentially via PDGFR-α pathway modulation. This intervention promoted remyelination and attenuated WMI and cognitive dysfunction in BCAS mice. Collectively, our results suggested that BPS mitigates chronic ischemic WMI by targeting OPC development, providing a potential therapeutic avenue for VCI.</div></div>","PeriodicalId":19139,"journal":{"name":"Neuropharmacology","volume":"278 ","pages":"Article 110547"},"PeriodicalIF":4.6000,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuropharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0028390825002539","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Chronic cerebral hypoperfusion (CCH) leads to white matter injury (WMI), a key contributor to the development of vascular cognitive impairment (VCI). Beraprost sodium (BPS) is a chemically stable and orally active prostaglandin I₂ (PGI₂) analog, while the role and mechanism of BPS in VCI have not been well understood. In this study, we used a mouse model of bilateral carotid artery stenosis (BCAS mice) and demonstrated that BPS treatment facilitated the proliferation and differentiation of oligodendrocyte precursor cells (OPCs), potentially via PDGFR-α pathway modulation. This intervention promoted remyelination and attenuated WMI and cognitive dysfunction in BCAS mice. Collectively, our results suggested that BPS mitigates chronic ischemic WMI by targeting OPC development, providing a potential therapeutic avenue for VCI.

查看原文本刊更多论文

贝拉前列素钠通过促进血管性认知障碍小鼠少突胶质前细胞增殖和分化改善认知障碍。

慢性脑灌注不足（CCH）导致脑白质损伤（WMI），是血管性认知障碍（VCI）发生的重要因素。Beraprost钠（BPS）是一种化学稳定且具有口服活性的前列腺素I2 （PGI2）类似物，其在VCI中的作用和机制尚不清楚。在这项研究中，我们使用双侧颈动脉狭窄小鼠模型（BCAS小鼠），证明BPS治疗促进了少突胶质前体细胞（OPCs）的增殖和分化，可能通过PDGFR-α通路调节。这种干预促进了BCAS小鼠的髓鞘再生，减轻了WMI和认知功能障碍。总之，我们的研究结果表明，BPS通过靶向OPCs的发展来减轻慢性缺血性WMI，为VCI提供了潜在的治疗途径。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neuropharmacology 医学-神经科学

CiteScore

10.00

自引率

4.30%

发文量

288

审稿时长

45 days

期刊介绍： Neuropharmacology publishes high quality, original research and review articles within the discipline of neuroscience, especially articles with a neuropharmacological component. However, papers within any area of neuroscience will be considered. The journal does not usually accept clinical research, although preclinical neuropharmacological studies in humans may be considered. The journal only considers submissions in which the chemical structures and compositions of experimental agents are readily available in the literature or disclosed by the authors in the submitted manuscript. Only in exceptional circumstances will natural products be considered, and then only if the preparation is well defined by scientific means. Neuropharmacology publishes articles of any length (original research and reviews).